Amulirafusp alfa - ImmuneOnco Biopharma
Alternative Names: IMM-0306Latest Information Update: 28 Dec 2024
At a glance
- Originator ImmuneOnco Biopharma
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD20 antigen inhibitors; CD47 antigen inhibitors; Macrophage stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Non-Hodgkin's lymphoma
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(In the elderly, Second-line therapy or greater, In adults) in USA (IV, Infusion)
- 07 Dec 2024 Pharmacokinetics, efficacy and adverse events data from a phase I/II trial in Non-Hodgkin's lymphoma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
- 07 Dec 2024 Adverse events data from a phase I/II trial in Non-Hodgkin's lymphoma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)